Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia

Current Pharmaceutical Design

Volumn 17, Issue 2, 2011, Pages 103-111

  Ferraris, Dana V ^a   Tsukamoto, Takashi ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

D amino acid oxidase; D serine; Nmda receptors; Schizophrenia

Indexed keywords

(5 METHYL 2 OXO 1,3 DIOXOL 4 YL)METHYL 4H FURO[3,2 B]PYRROLE 5 CARBOXYLATE; 1,4,5,6 TETRAHYDROCYCLOPENTA[B]PYRROLE 2 CARBOXYLIC ACID; 1H PYRROLE 2 CARBOXYLIC ACID DERIVATIVE; 1H PYRROLE 5 CARBOXYLIC ACID DERIVATIVE; 3 HYDROXYQUINOLIN 2(1H) ONE DERIVATIVE; 4 PHENETHYL 1H PYRROLE 2 CARBOXYLIC ACID; 4H FURO[3,2 B]PYRROLE 5 CARBOXYLIC ACID; 4H THIENO[3,2 B]PYRROLE 5 CARBOXYLIC ACID; 5 CHLORO BENZO[D]ISOXAZOL 3 OL; 5 METHYL 1H PYRAZOLE 3 CARBOXYLIC ACID; 5 PHENETHY 1H PYRAZOLE 3 CARBOXYIC ACID; 6H THIENO[2,3 B]PYRROLE 5 CARBOXYLIC ACID; CYCLOPENTANE FUSED PYRAZOLE 2 CARBOXYLIC ACID; DEXTRO AMINO ACID OXIDASE; DEXTRO AMINO ACID OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OXIDOREDUCTASE INHIBITOR; SERINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BRAIN; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; D-AMINO-ACID OXIDASE; ENZYME INHIBITORS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SERINE;

EID: 79953315208     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795049633     Document Type: Article

References (74)

1. Arana, GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61 Suppl 8; 5-11; discussion 12-3.
2. Shirzadi, AA, Ghaemi, SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14; 152-64.
3. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26; 365-84.
4. Javitt, DC, Zukin, SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148; 1301-8.
5. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994; 51; 199-214.
6. Yang CR, Svensson K A. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008; 120; 317-32.
7. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 2004; 55; 165-71.
8. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009; 12; 468-78.
9. Bridges TM, Williams R, Lindsley CW. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Curr Opin Mol Ther 2008; 10; 591-601.
10. Wolkenberg SE, Sur C. Recent progress in the discovery of nonsarcosine based GlyT1 inhibitors. Curr Top Med Chem 2010; 10; 170-86.
11. Hashimoto A, Nishikawa T, Hayashi T, et al. The presence of free D-serine in rat brain. FEBS Lett 1992; 296; 33-6.
12. Nagata Y, Horiike K, Maeda T. Distribution of free D-serine in vertebrate brains. Brain Res. 1994; 634; 291-5.
13. Hashimoto A, Nishikawa T, Oka T, Takahashi K. Endogenous Dserine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J Neurochem 1993; 60; 783-6.
14. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol 1971; 221; 1629-39.
15. Hashimoto A, Chiba Y. Effect of systemic administration of Dserine on the levels of D- and L-serine in several brain areas and periphery of rat. Eur J Pharmacol 2004; 495; 153-8.
16. Matsui T, Sekiguchi M, Hashimoto A, Tomita U, Nishikawa T, Wada K. Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem 1995; 65; 454-8.
17. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44; 1081-9.
18. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57; 577-85.
19. Ganote CE, Peterson DR, Carone FA. The nature of D-serine-- induced nephrotoxicity. Am J Pathol 1974; 77; 269-82.
20. Williams RE, Lock EA. Sodium benzoate attenuates d-serine induced nephrotoxicity in the rat. Toxicology 2005; 207; 35-48.
21. Burnet PW, Eastwood SL, Bristow GC, et al. D-amino acid oxidase activity and expression are increased in schizophrenia. Mol Psychiatry 2008; 13; 658-60.
22. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 2008; 101; 76-83.
23. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003; 60; 572-6.
24. Yamada K, Ohnishi T, Hashimoto K, et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol. Psychiatry 2005; 57; 1493-503.
25. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005; 29; 767-9.
26. Bendikov I, Nadri C, Amar S, et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90; 41-51.
27. Krebs HA. Metabolism of amino-acids. III. Deamination of aminoacids. Biochem. J. 1935; 29; 1620-0.
28. Hashimoto A, Oka T. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 1997; 52; 325-53.
29. Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 2000; 97; 4926-31.
30. Verrall L, Burnet PW, Betts JF, Harrison PJ. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry 2010; 15; 122-37.
31. Klein JR, Kamin H. Inhibition of the D-amino acid oxidase by benzoic acid. J Biol Chem 1941; 138; 507-512.
32. Klein JR, Olsen NS. Inhibitory effect of kojic acid upon oxidations mediated by liver and kidney. J Biol Chem 1947; 170; 151-157.
33. Bartlett GR. The inhibition of d-amino acid oxidase by benzoic acid and various monosubstituted benzoic acid derivatives. J Am Chem Soc 1948; 70; 1010.
34. Klein JR. Inhibition of D-amino acid oxidase by aromatic acids. J Biol Chem 1953; 205; 725-30.
35. Kawazoe T, Tsuge H, Pilone MS, Fukui K. Crystal structure of human D-amino acid oxidase: context-dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si-face of the flavin ring. Protein Sci 2006; 15; 2708-17.
36. Kawazoe T, Park HK, Iwana S, Tsuge H, Fukui K. Human Damino acid oxidase: an update and review. Chem Rec 2007; 7; 305-15.
37. Mattevi A, Vanoni MA, Todone F, et al. Crystal structure of Damino acid oxidase: a case of active site mirror-image convergent evolution with flavocytochrome b2. Proc Natl Acad Sci USA 1996; 93; 7496-501.
38. Pollegioni L, Diederichs K, Molla G, et al. Yeast D-amino acid oxidase: structural basis of its catalytic properties. J Mol Biol 2002; 324; 535-46.
39. Pollegioni L, Caldinelli L, Molla G, Sacchi S, Pilone MS. Catalytic properties of D-amino acid oxidase in cephalosporin C bioconversion: a comparison between proteins from different sources. Biotechnol Prog 2004; 20; 467-73.
40. Duplantier AJ, Becker SL, Bohanon MJ, et al. Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. J Med Chem 2009; 52; 3576-85.
41. Fang KQ, Hopkins S, Heffernan M, Chytil M. US7488747 (2009).
42. Kawazoe T, Tsuge H, Imagawa T, Aki K, Kuramitsu S, Fukui K. Structural basis of D-DOPA oxidation by D-amino acid oxidase: alternative pathway for dopamine biosynthesis. Biochem Biophys Res Commun 2007; 355; 385-91.
43. Adage T, Trillat AC, Quattropani A, et al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 2008; 18; 200-14.
44. Hamilton GA, Buckthal DJ. The inhibition of mammalian -amino acid oxidase by metabolites and drugs. Inferences concerning physiological function. Bioorg Chem 1982; 11; 350-370.
45. Frisell WR, Hellerman L, Lowe HJ. Flavoenzyme catalysis: substrate-competitive inhibition of D-amino acid oxidase. J Biol Chem 1956; 223; 75-83.
46. Huettner JE. Indole-2-carboxylic acid: a competitive antagonist of potentiation by glycine at the NMDA receptor. Science 1989; 243; 1611-3.
47. Talley JJ, Sprott K, Pearson JP, et al. US20100197708 (2010).
48. Wellner D, Scannone H. Oxidation of L-proline and L-3,4- dehydroproline by D-amino acid oxidase. Biochemistry 1964; 3; 1746-9.
49. Sparey T, Abeywickrema P, Almond S, et al. The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors. Bioorg Med Chem Lett 2008; 18; 3386-91.
50. Heffernan MLR, Dorsey JM, Fang QK, et al. US7579370 (2009).
51. Heffernan MLR, Dorsey JM, Fang QK, et al. US20080058395 (2008).
52. Heffernan MLR, Foglesong RJ, Hopkins SC, et al. US20080004327 (2008).
53. Heffernan MLR, Dennis R, Dorsey JM, et al. US20100120740 (2010).
54. Heffernan MLR, Fang QK, Foglesong RJ, et al. US20090099248 (2009).
55. Heffernan MLR, Fang QK, Foglesong RJ, et al. US20100029737 (2010).
56. Fang KQ, Hopkins S, Heffernan M, Chytil M, Wipf P. US7166725 (2007).
57. Kennis LEJ, Vanhoof GCP, Bongartz J.-pAM, Luyckx MGM, Minke WE. US20070197610 (2007).
58. Ferraris D, Duvall B, Ko YS, et al. Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J Med Chem 2008; 51; 3357-9.
59. Smith SM, Uslaner JM, Yao L, et al. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. J Pharmacol Exp Ther 2009; 328; 921-30.
60. Sit S.-Y, Ehrgott FJ, Gao J, Meanwell NA. 3-Hydroxy-quinolin-2- ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor. Bioorg Med Chem Lett 1996; 6; 499-504.
61. Morikawa A, Hamase K, Inoue T, Konno R, Niwa A, Zaitsu K. Determination of free D-aspartic acid, D-serine and D-alanine in the brain of mutant mice lacking D-amino acid oxidase activity. J Chromatogr B Biomed Sci Appl 2001; 757; 119-25.
62. Horiike K, Tojo H, Arai R, Nozaki M, Maeda TD-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain Res 1994; 652; 297-303.
63. Hashimoto K, Fujita Y, Horio M, et al. Co-administration of a Damino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 2009; 65; 1103-6.
64. Smith SM, Uslaner JM, Hutson PH. The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors. Open Med Chem J 2010; 4; 3-9.
65. Heefner DL, Currie MG, Richard Jr., FR, Zepp CM. US20030162825 (2003).
66. Horio M, Fujita Y, Ishima T, et al. Effects of D-Amino Acid Oxidase Inhibitor on the Extracellular D-Alanine Levels and the Efficacy of D-Alanine on Dizocilpine-Induced Prepulse Inhibition Deficits in Mice. Open Clin Chem J 2009; 2; 16-21.
67. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59; 230-4.
68. Labrie V, Fukumura R, Rastogi A, et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet 2009; 18; 3227-43.
69. Burch HB, Lowry OH, De Gubareff T, Lowry SR. Flavin enzymes in liver and kidney of rats from birth to weaning. J Cell Physiol 1958; 52; 503-10.
70. Nagata Y, Shimojo T, Akino TD-amino acid oxidase in mouse liver--II. Comp Biochem Physiol B 1988; 91; 503-4.
71. Holme DJ, Goldberg DM. Development of a fluorometric assay for amino-acid oxidase activity and its application to the study of human tissues. Biochem Med 1982; 28; 51-61.
72. Tsai GE, Lane HY, Vandenberg CM, Liu YC, Tsai P, Jann MW. Disposition of D-serine in healthy adults. J Clin Pharmacol 2008; 48; 524-7.
73. Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy) phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 2010; 53; 4603-14.
74. Lindsley C. GlyT1 - Up from the ashes. The importance of not condemning a mechanism based on a single chemotype. ACS Chem Neurosci 2010; 1; 165-166.